Royal Bank of Canada’s Actuate Therapeutics ACTU Stock Holding History

Royal Bank of Canada’s Portfolio ACTU Stock Details ACTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1K	Sell	483 -21,742	-98%	-$50.4K	﹤0.01%	7295
2026 Q1	$61K	Sell	22,225 -13,038	-37%	-$54K	﹤0.01%	5392
2025 Q4	$215K	Buy	35,263 +22,309	+172%	+$153K	﹤0.01%	4705
2025 Q3	$86K	Buy	12,954 +11,627	+876%	+$84.3K	﹤0.01%	5586
2025 Q2	$8K	Sell	1,327 -17,211	-93%	-$150K	﹤0.01%	6550
2025 Q1	$126K	Buy	18,538 +18,236	+6,038%	+$146K	﹤0.01%	5061
2024 Q4	$2K	Sell	302 -34,998	-99%	-$286K	﹤0.01%	6741
2024 Q3	$263K	Buy	+35,300	New	+$279K	﹤0.01%	4600

Other funds holding ACTU

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return

PVM

Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ADEF

ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Royal Bank of Canada's ACTU Position: Q2 2026 in Review

Royal Bank of Canada reduced its Actuate Therapeutics (ACTU) stake by 98% in Q2 2026, selling an estimated $50.4K and leaving 483 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #7295.

Royal Bank of Canada first reported a position in ACTU in Q3 2024 and has held it in 8 quarters since. The position peaked at $263K in Q3 2024. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

Royal Bank of Canada held 483 shares of Actuate Therapeutics worth $1K as of Q2 2026.
Royal Bank of Canada sold 21,742 Actuate Therapeutics shares in Q2 2026, an estimated $50.4K.
Actuate Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #7295 holding.
Royal Bank of Canada first reported a position in Actuate Therapeutics in Q3 2024 and has held it in 8 quarters since.
Royal Bank of Canada's Actuate Therapeutics position peaked at $263K in Q3 2024.
63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.